0
Clinical Investigations: SURGERY |

Quality of Life After Coronary Artery Bypass Graft*: Results From the POST CABG Trial

Norma Lynn Fox, PhD, MPH; Byron J. Hoogwerf, MD; Susan Czajkowski, PhD; Ruth Lindquist, PhD; Gilles Dupuis, PhD; J. Alan Herd, MD; Lucien Campeau, MD; Ann Hickey, MD; Franca B. Barton, MS; Michael L. Terrin, MD, MPH, FCCP; for the POST CABG Study Investigators
Author and Funding Information

Affiliations: *From the Maryland Medical Research Institute (Drs. Fox and Terrin, and Ms. Barton), Baltimore, MD; Cleveland Clinic Foundation (Dr. Hoogwerf), Cleveland, OH; National Heart, Lung, and Blood Institute (Dr. Czajkowski), Bethesda, MD; University of Minnesota (Dr. Lindquist), Minneapolis, MN; Montreal Heart Institute (Drs. Dupuis and Campeau), Montreal, PQ, Canada; Cedar Sinai Medical Center (Dr. Hickey), Los Angeles, CA; and Baylor College of Medicine (Dr. Herd), Houston, TX.,  POST CABG Studies Investigators listed in references 1 and 21.

Correspondence to: Norma Lynn Fox, PhD, MPH, Human Genome Sciences, Inc., Rockville, MD 20850; e-mail normalynn_fox@HGSI.com



Chest. 2004;126(2):487-495. doi:10.1378/chest.126.2.487
Text Size: A A A
Published online

Objectives: The POST CABG (Post Coronary Artery Bypass Graft) Trial showed that aggressive lowering of low-density lipoprotein (LDL) cholesterol levels reduced the progression of atherosclerosis in saphenous vein grafts. In the extended follow-up phase, aggressive lowering of LDL cholesterol levels was associated with reduced rates of clinical events. Low-dose anticoagulation therapy did not reduce the progression of atherosclerosis. We conducted this analysis to determine the effects of both lipid-lowering and low-dose anticoagulation therapy on health-related quality of life (HRQL).

Design: Randomized clinical trial, factorial design.

Setting: Outpatients in five tertiary care medical centers.

Patients: A cohort of 852 patients enrolled in the POST CABG Trial completed an HRQL questionnaire at baseline, and at the year 2 and year 4 follow-up visits.

Intervention: Aggressive LDL cholesterol lowering vs moderate LDL cholesterol lowering, and low-dose warfarin vs placebo.

Measurements: Domains included emotional status, basic physical and social functioning, perceived health status, symptoms of pain, a variety of physical symptoms, and global life satisfaction.

Results: Overall, there were no indications of systematic differences among treatment groups for any of the HRQL parameters at baseline, year 2, or year 4.

Conclusions: These data indicate that patients did not experience detrimental or beneficial effects on HRQL parameters while receiving LDL cholesterol-lowering therapy that had demonstrable benefits for treatment of atherosclerosis.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543